Jazz Pharmaceuticals
jazzpharma.comTotal trials
200
Active
20
Phase 3
71
Total enrollment
29,883
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 30 of 30 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Cannabidiol | — | — | — | — | — | 1 | |
| Zanidatamab | — | — | — | 7 | |||
| Trastuzumab | — | — | — | — | 3 | ||
| Capecitabine | — | — | — | 4 | |||
| Gemcitabine | — | — | — | — | 4 | ||
| Cisplatin | — | — | — | — | 3 | ||
| Pembrolizumab | — | — | — | — | 2 | ||
| Durvalumab | — | — | — | — | 2 | ||
| Dordaviprone | — | — | — | 5 | |||
| Vinorelbine | — | — | — | — | 2 | ||
| Oxaliplatin | — | — | — | — | 2 | ||
| Tislelizumab | — | — | — | — | — | 1 | |
| 5-Fluorouracil | — | — | — | — | — | 1 | |
| Dordaviprone (ONC201) + Placebo | — | — | — | — | — | 1 | |
| Eribulin | — | — | — | — | — | 1 | |
| ONC206 | — | — | — | — | 2 | ||
| Lurbinectedin | — | — | — | — | 4 | ||
| Paclitaxel | — | — | — | — | 2 | ||
| Docetaxel | — | — | — | — | — | 1 | |
| Carboplatin | — | — | — | — | — | 1 | |
| Pertuzumab | — | — | — | — | — | 1 | |
| JZP3507 | — | — | — | — | — | 1 | |
| ONC206: Dose 1 | — | — | — | — | — | 1 | |
| ONC206: Dose 2 | — | — | — | — | — | 1 | |
| JZP047 | — | — | — | — | — | 1 | |
| CBD-OS | — | — | — | — | — | 1 | |
| JZP898 | — | — | — | — | — | 1 | |
| JZP815 | — | — | — | — | — | 1 | |
| Epidiolex | — | — | — | — | — | 2 | |
| Epidiolex 100 mg/mL Oral Solution | — | — | — | — | — | 1 |
Next readouts
- 2026-07
- 2026-07
- 2026-07-05
- 2026-07-31
- 2026-12-31
- 2027-02
- 2027-08-01
- 2027-11-29
- 2027-11-30
- 2028-01-01
Top conditions
- Narcolepsy14
- Epilepsy14
- Pain14
- Multiple Sclerosis13
- Acute Myeloid Leukemia10
- Spasticity6
- Glioma5
- Acute Lymphoblastic Leukemia5
Frequently asked questions about Jazz Pharmaceuticals
- How many clinical trials does Jazz Pharmaceuticals have on ClinicalTrials.gov?
- Jazz Pharmaceuticals is listed as the lead sponsor on 200 clinical trials in ClinicalTrials.gov, 20 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Jazz Pharmaceuticals's trials are in Phase 3?
- 71 of Jazz Pharmaceuticals's trials are in Phase 3, spread across 30 active drug programs.
- What therapeutic areas does Jazz Pharmaceuticals focus on?
- Jazz Pharmaceuticals's most-studied conditions on ClinicalTrials.gov are Narcolepsy, Epilepsy, Pain, Multiple Sclerosis, Acute Myeloid Leukemia.
- When are Jazz Pharmaceuticals's next clinical trial readouts?
- Jazz Pharmaceuticals has 10 upcoming primary-completion readouts tracked here; the soonest is “Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms”, expected around 2026-07.